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Abstract
With more than 1.4 million of the 9 million child deaths being attributed to diarrhoea in 2008 and 49% of them
occurring in five countries namely, India, Nigeria, Democratic Republic of the Congo, Pakistan and China, there is
an urgent need for intervention to prevent and control diarrhoeal diseases. Of the various interventions, probiotics
offer immense potential. The past decade has witnessed the validation of their utility for the prevention, treatment
and management of a variety of infective and non infective disorders. The most investigated field continues to
remain infectious diarrhoea and compelling evidence comes from randomized placebo controlled trials. While
results from these studies are encouraging most of them reflect the outcomes of the developed world. Developing
countries like India continue to struggle with nutritional and health challenges and bear the greatest burden of
diarrhoea. A paucity of data from the developing countries limits the definite recommendation of probiotics. In
these countries curd, often confused for a probiotic, is practiced as an integral part of the culture. While the nutri-
tional benefits of these products cannot be understated, it is still uncertain whether these products can be classi-
fied as a probiotic. The emergence of probiotic foods which are scientifically validated for their efficacy and impart
defined health benefits offer an excellent opportunity to improve public health. A recent randomized controlled
trial conducted by the National Institute of Cholera and Enteric Diseases in Kolkata, India demonstrated a protective
efficacy of 14% in preventing diarrhoea among children who received a probiotic. For the developing world how-
ever the vision for probiotics would mean a fundamental change in perception and developing a well planned
strategy to allow interventions like probiotics to permeate to impoverished settings, where the assault of micro
organisms is on a daily basis. This would mean that probiotics are ingrained into the public health system without
being seen as a medicine.
Dr. Elie Metchnikoff, a Russian laureate, is credited with
introducing the concept that live microorganisms are
beneficial for health. In 1965, this concept was forma-
lized by introduction of the term “Probiotics” by Lilly
and Stilwell to define growth promoting factors pro-
duced by microorganisms. Although the concept of pro-
biotics goes back to the Vedic times, the science has
taken a giant leap only in the recent past. A substantial
part of this new-found interest stems from the unprece-
dented advancement in our understanding of the role of
the intestinal microbiota. A few decades ago, only 400
bacterial communities were reported to colonize the dis-
tal human gut. The development of metagenomics sup-
ported by high throughput sequencing has launched this
number to about 1000 communities [1]. More
importantly, there is substantial progress in understand-
ing the function, autochthony and microbial ecology of
this complex ecosystem. The intestinal microbiota today
is thought to be an organ that works like a well orche-
strated symphony in health and can be manipulated to
improve health, when in disease.
These insights have led to escalation in probiotic
research resulting in significant expansion of the probio-
tic arena especially in the Western world with more
than 500 new stock keeping units globally in the probio-
tic foods and beverages sector [2]. Research Institutes
solely working on probiotics have mushroomed in many
parts of the developed world. There is however a dis-
tinct difference between the Western and the Eastern
perspective on the use of probiotics. While in the West
they are considered a revolution and viewed as a means
for maintaining a balanced gut flora geared towards
optimum health, in Asia and the Orient probiotics
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any medium, provided the original work is properly cited.continue to remain a scientific curiosity, a clinicians’
dilemma and a confusing entity to the general public as
to what makes them different from traditional foods.
Probiotics find use in a variety of diseases including
diarrhoea and although several products are becoming
increasingly available they are not commonly recom-
mended. The possible use of probiotics as a public
health strategy such as improved sanitation or delivery
of safe drinking water is not contemplated and the rural
and urban poor areas have largely been neglected. Ironi-
cally, it is this group that has the heaviest burden of
diarrhoea, acute respiratory infections and a host of
other infectious diseases [3]. Poverty is a defining factor
in the high burden of diarrhoea and also a defining fac-
tor for the exclusion of health benefits derived from
interventions like probiotics. In this editorial, we debate
on how probiotics should be used as a public health
strategy to prevent diarrhoea in populations where the
need is the greatest.
The definition of probiotics has been widely debated,
but in 2001 FAO and WHO defined them as “Live
microorganisms which when administered in adequate
amounts confer a health benefit on the host” [4]. This
universally accepted definition implies that a probiotic
strain unless protected by a capsule should be intrinsi-
cally resistant to low pH, bile and pancreatic enzymes to
ensure GI transit in numbers adequate enough to elicit
a defined benefit to the host. It was then recognized
that the concept of probiotics is essentially to improve
host health by modifying the composition of the intest-
inal microbiota. The recent advent of powerful molecu-
lar techniques have made it possible to monitor changes
in the gut micro biota following probiotic administration
thereby enabling better understanding of their function.
This has also helped to recognize the fact that probiotics
offer remarkable potential for the prevention and man-
agement of various infective and non infective disorders.
Scientific evidence points to the fact that the ability of a
probiotic bacteria to confer a health effect largely
depends on the particular strain being used [5]. There
has thus been a resurgence of interest about the strain
specific benefits of probiotics and clinical research is
quickly accumulating to support the evidence for their
use. The scope and scale of the potential of probiotics is
staggering and the full spectrum of their benefit to
human health is still being investigated.
With the realization of what it takes to classify as a
true probiotic it remains uncertain whether curd and
other dairy products are actually probiotic. According to
The Prevention of Food Adulteration Act and Rules,
1955 [6], curd is defined as a product obtained from
souring of boiled or pasteurized milk naturally, by harm-
less lactic acid bacteria or other bacterial cultures
[A. 11.02.04 of Appendix B, Definitions and Standards
of quality] whereas Yoghurt is obtained by lactic acid
fermentation of milk by Lactobacillus delbreuckii ssp.
bulgaricus and Streptococcus thermophilus.I tm a ya l s o
contain Bifidobacterium bifidus and Lactobacillus acido-
philus and other cultures of harmless lactic acid produ-
cing bacteria which if added must be declared
[A. 11.02.17 of Appendix B, Definitions and Standards
of quality]. While one cannot undermine the nutritional
benefits of these products, it still remains to be deter-
mined whether these products contain organisms that
are defined in terms of number, viable at the target site
and proven for their ability to impart strain specific ben-
efits. Therefore the emergence of probiotic foods which
are scientifically validated for their efficacy and impart
defined health benefits offer an excellent opportunity to
improve public health and the category is receiving far
more attention than what was originally conceptualized.
India with its growing awareness and need for preven-
tive medicine is also witnessing the entry of a surge of
probiotic foods which are rapidly finding their way onto
the market shelves. But would these products really find
use in a developing country like India still remains to be
seen.
Around 1.4 million of the 9 million child deaths in
2008 were due to diarrhoea with 49% of the deaths
occurring in five countries namely India, Nigeria, Demo-
cratic Republic of the Congo, Pakistan and China [3,7].
In 2008, diarrhoea killed more children than AIDS,
malaria and measles combined. Progress has been made
in some areas of diarrhoea prevention. These include
vitamin A supplementation, immunization, access to
safe drinking water and exclusive breast feeding [7,8].
However, current estimates show that 2.5 billion people
still lack access to improved sanitation facilities and
1 billion lack access to improved drinking-water sources.
The other attendant effects of diarrhoea include under-
weight or stunting which causes about 20% of all
mortality of children younger than 5 years of age [9].
Unless, these statistics improve diarrhoea will continue
to remain a formidable but largely neglected problem in
many parts of the developing world.
The rationale for using probiotics in acute infectious
diarrhoea is based on the assumption that they act
against intestinal pathogens and possible mechanisms
include the synthesis of antimicrobial substances, com-
petitive inhibition of adhesion of pathogens, modifica-
tion of toxin and non toxin receptors and stimulation of
non specific and specific immune responses to patho-
gens. While research using probiotics has extended to a
vast array of diseases, the most investigated field con-
tinues to remain infectious diarrhoea and compelling
evidence comes from randomized placebo controlled
trials. Data extrapolated from a large body of studies
that include systemic reviews [10-13] meta analysis
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testing the efficacy of probiotics in preventing diarrhoea
concluded that besides demonstrating a good safety pro-
file probiotics significantly reduced the duration and fre-
quency of acute diarrhoea. A meta-analysis of acute
pediatric diarrhoea concluded that there was significant
data for probiotic based reduction of diarrhoea duration,
treatment failure and prevention [21]. Different strains
of Lactobacilli have also shown benefit in reducing
the duration of rotaviral shedding; an observation that
has favorable epidemiologic implications [19,22].
A Cochrane review suggests that probiotics may appear
to be a useful adjunct to rehydration therapy when
managing both adults and children [10]. The beneficial
effects of probiotics however are strain dependent, dose
dependent, greater for doses of more than 10
10 cfu, sig-
nificant in people with viral gastroenteritis and more
evident when treatment with probiotics is initiated early
i nt h ec o u r s eo ft h ed i s e a s e[ 2 3 ] .I ti sm o r ed i f f i c u l tt o
assess benefit in adults due to the range of strains, pro-
ducts studied and a lack of identification of the patho-
gens involved. However, recently there has been
convincing evidence for probiotic reduction of the risk
of antibiotic associated diarrhoea and conclude potential
for Lactobacillus species and Saccharomyces boulardii
probiotics [12,14,16,21,24]. These findings were substan-
tiated by a careful meta analysis by D’ Souza et al [24]
that found probiotics more effective than placebo.
Although the results from these studies appear to be
encouraging, they come with one major disadvantage -
most of them reflect the outcomes of the developed
world. Therefore, while they have resulted in changing
the face of the health map in the Western world, the
developing world continues to grapple because of a pau-
city of data and the concept remains unproven and
blurred. The goal is to set the stage. A leap forward
would mean taking cue from the findings of the devel-
oped world that could herald probiotic usage in a coun-
t r yl i k eI n d i aw h i c hc o n t i n u e st os t r u g g l ew i t h
nutritional and health challenges and hence bears the
highest burden of diarrhoea [3]. While a number of stu-
dies evaluating the role of probiotics in preventing diar-
rhoea have been conducted in the developing world
they have failed to document any significant benefit
[25-27]. Most of the trials that have been conducted in
India to evaluate the prophylactic and therapeutic role
of various probiotic strains in diarrhoea have focused on
children but unfortunately have shown mixed results
[28-31]. While some have shown benefit others have
demonstrated no visible difference. This has limited
their definite recommendation and therefore calls for
design of studies that would allow definite use of a par-
ticular probiotic strain. This more so given that a sub-
stantial pediatric hospital admission is due to acute
watery diarrhoea which strain the hospital resources and
significantly impact on the economic burden of the
country. Probiotics in the form of a ubiquitous, simple,
safe intervention, if found effective in limiting the dura-
tion of diarrhoea, would be a welcome addition to the
strategy of containment of diarrhoea related complica-
tions. A recent community based trial on more than
3000 children at the National Institute of Cholera and
E n t e r i cD i s e a s e s ,K o l k a t aw h e r et h eu s eo fap r o b i o t i c
strain Lactobacillus casei strain Shirota showed a pro-
tective efficacy of 14% in preventing acute diarrhoea
brings a ray of hope [32].
However in countries where curd, often confused for a
probiotic, forms an integral part of the culture, the con-
cept is bound to be met with much resistance and skep-
ticism. It is thus about entering a new, unchartered
territory. Unfortunately compelling scientific evidence
from the West is not enough to substantiate belief
about the health benefits of probiotics when it comes to
key regulators and policy makers. This is with good rea-
son given that poly microbial diarrheal infections are
common in these settings. It is therefore not surprising
that while the growing scientific developments in the
area are setting public, industry and scientific research
agendas on one hand, on the other it has led to a wave
of concern raising a number of critical questions which
are fundamentally different from those raised in the
past. Key concerns are: can experts be believed, do pro-
biotics do what they say, for how long does one con-
sume them to get a health benefit, do they provide any
additional benefit than that conferred by regular con-
sumption of curd, are they scientifically validated for
their efficacy, are they affordable, what is the interpreta-
tion of risk, disease and illness, regulation and public
health impact. A frequently asked question relates to the
dose of a probiotic that needs to be ingested to trigger
an effect. Often key debate on the use of probiotics cen-
ters on their ability to colonize the Indian gut, which
because of multiple pathogen onslaught is microbiologi-
cally more hostile and is therefore considered to be dif-
ferent from that of the Western counterpart. Also
whether a probiotic would confer a similar response in
both the settings. A key goal of probiotic science would
thus be to understand and target particular biomarkers
and end points for the disease and the specific strains
that act upon this. Put simply the scientific challenge is
about identifying the strain specific benefits.
F r o mar e g u l a t o r ys t a n d p o i n ta l s ot h i sa r e ai sh i g h l y
unregulated. Looking at the global scenario, probiotics
f a l li n t oag r e yr e g u l a t o r ya r e ab e c a u s er e g u l a t i o n sf o r
probiotics are nonexistent in most countries. Whatever
the regulations they differ from country to country and
within the same country the way the product is regulated.
Japan is by far the most advanced in terms of regulations
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fare (MHLW) having set up “Foods for Specified Health
Use” (FOSHU) in 1991 as a regulatory system to approve
the statements made on food labels [33]. In India there is
no regulatory framework for probiotics in food, however
the category is expected to witness rapid growth in the
coming years. In the absence of any regulatory standards
and guidelines there would always be a possibility of pro-
ducts that are unreliable in content and contain strains
whose scientific efficacy has not been validated. Hence it
becomes imperative that these products are standardized
and fulfill the desired effect through evidence based stu-
dies which is what prompted the Indian Council of Medi-
cal Research (ICMR) and Department of Biotechnology
(DBT) to establish a set of guidelines that would ensure
product safety, quality, reliability and level playing for all
companies introducing and producing probiotic pro-
ducts. These guidelines when implemented would have a
provision for assessment of efficacy; safety and health
claims made by the probiotic foods that are being
launched [34]. Despite this the main concern that con-
tinues to surround most critics is whether probiotics
represent just another trend and hence the question
often is where is the dividing line - in other words just
how much science is enough, what are the implications
for their use and should recommendations be made to
the public. The list of questions and more questions is
endless and the application of probiotics continues to
remain a paradox. Thus despite the fact that probiotics
represent a unique perspective for improvement of health
the optimism that probiotics accrue in terms of benefit is
counter balanced by a series of ‘ifs’ and ‘buts’ limiting
their definite recommendation for a developing country
like India.
For the developing world, therefore the vision for pro-
biotics would mean a fundamental change in perception.
It means developing a diet based intervention strategy
a n df o r m u l a t i n gf o o d st a i l o r e dt om e e tt h es p e c i f i c
health needs. However a developing country often faces
challenges from changing demographic profiles, seden-
tary lifestyles, higher disposable income on one hand to
deepening poverty on the other. It therefore becomes
important that the probiotic claim acts as a significant
signal of value appealing to the consumers growing
interest in the link between their diet and their health
justifying a significant price premium. It remains uncer-
tain though whether probiotics are seen as an interven-
tion for healthy individuals or those who are ill and
have a medical condition or for both. This important
distinction therefore needs to be made.
While the probiotic revolution promises to take health
to new heights or as the scientists openly say to new
frontiers, the most effective direction to take continues
to be the subject of much debate which will lead to
arguments for and arguments against and will include
that some of the major issues such as efficacy in the
given scenario, and acceptable outcomes should be
reached. This editorial begs the question whether pro-
biotics will contribute to public health goals or simply
be seen as addressing a narrow range of unsubstantiated
individual effects. The challenge in the next few years
would be to develop a well planned strategy to allow
interventions like probiotics to permeate to impover-
ished settings where the assault of microorganisms,
pathogenic or otherwise, is on a daily basis. Such set-
tings are very different from the sanitized West or the
affluent sections in the East. The challenge for a probio-
t i ct of i n di t sw a yt ot h em a s s e sw o u l db eg o v e r n e db y
costs, compliance, and concept on how to get this
ingrained into the public health system without being
seen as a medicine.
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